List of Excipients in Branded Drug OLUX-E

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	OLUX-E	clobetasol propionate	0378-8147	ANHYDROUS CITRIC ACID
Mylan Pharmaceuticals Inc	OLUX-E	clobetasol propionate	0378-8147	CETYL ALCOHOL
Mylan Pharmaceuticals Inc	OLUX-E	clobetasol propionate	0378-8147	CYCLOMETHICONE
Mylan Pharmaceuticals Inc	OLUX-E	clobetasol propionate	0378-8147	ISOPROPYL MYRISTATE

OLUX-E Excipient Strategy and Commercial Opportunities for Clobetasol Propionate Foam

Last updated: October 21, 2026

OLUX-E is a topical clobetasol propionate 0.05% emollient foam designed to improve application, spreadability, and skin feel relative to ointments, creams, and conventional aerosol foams. Its commercial opportunity is strongest in differentiated generic and authorized-generic products that preserve the foam’s sensory profile while reducing formulation cost, improving packaging efficiency, or targeting underserved dermatology channels.

The product’s key formulation assets are its anhydrous or low-water foam system, volatile propellant delivery, emollient phase, alcohol-based evaporation profile, and surfactant-stabilized structure. The main commercial risks are high-potency corticosteroid labeling restrictions, limited treatment duration, formulation-equivalence requirements, device and container compatibility, and competition from lower-cost clobetasol creams, gels, solutions, shampoos, and non-emollient foams.

What is OLUX-E and how is it positioned?

OLUX-E is a prescription topical aerosol foam containing clobetasol propionate 0.05%, a super-high-potency corticosteroid. The product is indicated for the short-term topical treatment of mild-to-moderate plaque psoriasis and atopic dermatitis in patients aged 12 years and older, subject to product labeling and duration restrictions.[1]

The product is positioned around delivery performance rather than a new active ingredient. Its value proposition includes:

• Rapid foam formation and easy spreading.
• Reduced residue compared with ointments.
• Emollient skin feel.
• Practical use on hairy or difficult-to-reach areas.
• A familiar high-potency corticosteroid active ingredient.
• Aerosol convenience for patients who dislike creams or ointments.

OLUX-E is therefore a formulation-led product. The commercial value is concentrated in the vehicle, dispensing system, sensory characteristics, and patient-use experience.

What excipients are used in OLUX-E?

The OLUX-E formulation uses a combination of fatty alcohols, solvent and humectant components, buffering agents, surfactant, mineral oil, water, and hydrofluorocarbon propellant.[1,2]

Excipient or component	Likely formulation role	Commercial relevance
Cetyl alcohol	Emollient, consistency agent, foam-structure contributor	Supports skin feel and product body
Stearyl alcohol	Emollient, thickener, co-structurant	Helps stabilize the emollient phase
Light mineral oil	Occlusive emollient	Differentiates OLUX-E from less emollient foam vehicles
Polysorbate 60	Nonionic surfactant and emulsifier	Helps disperse oily and aqueous components
Ethanol	Volatile solvent and evaporation aid	Supports rapid drying and application feel
Propylene glycol	Solvent, humectant, penetration-supporting vehicle component	Can improve wetting and skin hydration but may cause irritation in sensitive patients
Citric acid and potassium citrate	Buffer system and pH control	Supports chemical stability and skin compatibility
Purified water	Aqueous phase	Influences stability, microbial control, and foam behavior
Hydrofluorocarbon propellant	Aerosol generation and product expulsion	Creates packaging, pressure, and environmental compliance requirements

The excipient strategy balances four competing objectives: maintaining clobetasol stability, producing a uniform foam, delivering adequate skin coverage, and minimizing greasy residue. The inclusion of mineral oil and fatty alcohols gives OLUX-E a more emollient profile than a simple alcohol-water foam.

How does the OLUX-E vehicle compare with other clobetasol formulations?

OLUX-E competes against several dosage forms containing the same active ingredient. The vehicle often determines the practical commercial position more than the corticosteroid itself.

Product type	Typical vehicle profile	Patient-use advantage	Commercial weakness
Ointment	Petrolatum-rich, highly occlusive	Strong moisturization and barrier support	Greasy, difficult to apply to hair-bearing areas
Cream	Emulsion with moderate residue	Familiar and broadly acceptable	Less differentiated and often heavily commoditized
Solution	Alcohol- or solvent-based	Useful for scalp and hairy areas	More drying and potentially irritating
Gel	Hydroalcoholic or polymer-based	Fast drying and low residue	May sting or dry inflamed skin
Shampoo	Wash-off vehicle	Scalp convenience	Short contact time and narrower use case
Conventional foam	Lightweight, rapidly spreading	Good application experience	May provide less emollient feel
OLUX-E	Emollient aerosol foam	Spreading, drying, and moisturization balance	Higher packaging and formulation complexity

The most direct comparison is with clobetasol propionate foam products that use a less emollient vehicle. OLUX-E may command a premium when patients value low residue and easy application, but the premium is vulnerable to generic substitution and payer preference for lower-cost formulations.

What commercial opportunities exist for OLUX-E excipient technology?

The primary opportunity is a generic or branded-generic product that matches the reference product’s formulation performance without reproducing unnecessary cost. Four commercial routes are available.

1. Generic clobetasol propionate emollient foam

A generic applicant can pursue an ANDA referencing the listed drug. The development burden is higher than for a conventional cream because the applicant must demonstrate product quality, device performance, container compatibility, and comparable product performance. The most commercially valuable attributes are:

• Foam density and collapse time.
• Dose delivered per actuation.
• Droplet or bubble-size distribution.
• Clobetasol content uniformity.
• Spreadability and drying time.
• Residual greasiness.
• Formulation viscosity before dispensing.
• Stability under temperature cycling.
• Consistent performance near the end of canister life.

A lower-cost product that retains these attributes could compete effectively in dermatology formularies and specialty pharmacies.

2. Authorized generic or private-label supply

An authorized generic can exploit existing manufacturing know-how and reduce development risk. The opportunity is strongest where the product owner has underused manufacturing capacity, a mature aerosol filling network, or access to dermatology distribution channels.

Private-label commercialization can also target:

• Managed-care formularies.
• Hospital outpatient pharmacies.
• Dermatology group purchasing organizations.
• Teledermatology platforms.
• Cash-pay prescription channels.
• International markets with less crowded topical corticosteroid categories.

3. Excipient optimization

The formulation can be optimized through substitution or concentration adjustment of nonactive ingredients, provided the final product maintains performance and regulatory acceptability. Potential objectives include:

• Reducing ethanol-related irritation.
• Replacing or reducing propylene glycol for sensitive-skin populations.
• Improving emollience without increasing residue.
• Lowering canister weight.
• Reducing hydrocarbon or propellant content.
• Improving foam collapse and skin coverage.
• Increasing chemical stability under accelerated storage.
• Reducing raw-material cost.
• Improving compatibility with alternative aerosol valves and actuators.

Excipient substitution is commercially attractive but carries risk. A seemingly minor change in fatty alcohol ratio, surfactant level, buffer capacity, or propellant composition can alter foam structure, spray pattern, dose delivery, evaporation rate, and patient perception.

4. Sustainable aerosol and packaging redesign

The current product architecture creates an opportunity for packaging innovation. Potential approaches include:

• Lower-global-warming-potential propellant systems.
• Bag-on-valve packaging.
• Metered-dose aerosol systems.
• Alternative actuator geometries.
• Reduced-material canisters.
• Improved residual-product recovery.
• Recyclable or partially recyclable packaging.

A packaging change may create a differentiated product, but it can also trigger new equivalence, stability, device-performance, and human-factors requirements. The commercial case depends on whether sustainability claims produce payer, pharmacy, or prescriber value.

Which excipients create the strongest differentiation?

The most defensible technical differentiation is likely to arise from the interaction among mineral oil, fatty alcohols, surfactant, propylene glycol, ethanol, and propellant rather than from any single excipient.

Mineral oil and fatty alcohol ratio

Mineral oil supports occlusion and moisturization. Cetyl and stearyl alcohols contribute to texture, emulsion structure, and foam persistence. Adjusting their ratio can change:

• Product glide.
• Residue.
• Skin hydration.
• Foam creaminess.
• Actuation consistency.
• Stability during storage.

This combination is commercially important because it determines whether a product is perceived as a genuinely emollient foam or as a conventional aerosol with a thin solvent vehicle.

Ethanol and propylene glycol balance

Ethanol accelerates drying and helps dissolve or distribute formulation components. Propylene glycol supports solvency and moisturization. Higher levels may improve processing or delivery but increase irritation potential for some patients.

A commercial developer could target a lower-irritation profile, but any change must be assessed against clobetasol solubility, crystallization risk, microbial control, drying time, and skin penetration.

Polysorbate 60

Polysorbate 60 supports dispersion of the oily phase. It can affect emulsion stability, foam texture, and long-term product uniformity. Surfactant concentration also matters for skin tolerability and compatibility with container components.

Buffer system

Citric acid and potassium citrate provide pH control. Buffer capacity can influence active stability, preservative performance, skin comfort, and packaging corrosion. A different buffer system may be possible, but pH alone does not establish equivalence. The entire formulation and product-performance profile must be evaluated.

What FDA regulatory issues affect an OLUX-E generic?

An OLUX-E generic would generally proceed through the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, with requirements tailored to a complex topical dosage form.[3]

For a foam aerosol, the critical regulatory package may include:

• Active ingredient identity, strength, and quality.
• Inactive ingredient controls.
• Comparative formulation information.
• Container-closure and valve specifications.
• Actuation and delivered-dose testing.
• Spray pattern and plume characterization.
• Foam density and collapse testing.
• Particle or droplet-size characterization.
• Microbiological quality.
• Extractables and leachables assessment.
• Stability under long-term and accelerated conditions.
• Comparative product-performance testing.
• Manufacturing-process validation.

The FDA’s recommendations for topical dermatological products recognize that locally acting products may require multiple comparative tools, including in vitro release testing, in vitro permeation testing, and other product-quality comparisons depending on the dosage form.[4]

A developer should treat the canister, valve, actuator, propellant, and formulation as an integrated drug-delivery system. Changing the excipient system without evaluating the delivery hardware can create a product that is chemically equivalent but operationally different.

What patent and exclusivity issues affect OLUX-E?

OLUX-E’s commercial protection has historically depended more on formulation and product-specific intellectual property than on new-molecule exclusivity. Clobetasol propionate is an established corticosteroid, so the strategic questions concern formulation patents, device claims, method-of-use claims, and Orange Book-listed patents rather than active-ingredient exclusivity.

The relevant diligence areas are:

Issue	Commercial question
Orange Book listing	Which patents, if any, are listed for the reference product?
Formulation claims	Do claims cover the emollient foam composition or excipient ranges?
Device claims	Do claims cover the canister, valve, actuator, or dispensing system?
Manufacturing claims	Are there protected methods for producing or filling the foam?
Method-of-use claims	Are psoriasis, atopic dermatitis, scalp, or age-specific uses claimed?
Paragraph IV risk	Can an ANDA applicant challenge listed patents before expiry?
Patent-term adjustment	Has the relevant expiration date moved from the nominal term?
Settlement agreements	Are there restrictions on generic launch or authorized-generic competition?

A definitive patent-expiration analysis requires a current Orange Book record, patent listings, prosecution history, and litigation docket review. Patent strength should be assessed claim by claim. Broad composition claims may be vulnerable to prior art involving clobetasol foams, aerosol emulsions, fatty alcohols, mineral oil, and related dermatological vehicles. Narrow claims covering specific excipient ratios, foam properties, or device configurations may be more difficult to design around but also easier to attack for lack of written description, enablement, or obviousness.

What generic launch risks exist for OLUX-E?

The largest launch risk is not active-ingredient supply. It is the ability to reproduce the reference product’s performance at commercial scale.

Key risks include:

1. Foam instability. The product may separate, lose structure, or show inconsistent collapse after storage.
2. Dose variability. Actuation force, valve behavior, and canister pressure can change delivered dose.
3. Clobetasol crystallization. Changes in solvent composition may reduce dissolved active and alter release.
4. Container interaction. The formulation can interact with coatings, gaskets, valves, or actuator materials.
5. Sensory mismatch. A product can meet chemical specifications but be rejected by patients because it feels wetter, greasier, stickier, or more irritating.
6. Manufacturing scale-up. Laboratory mixing and filling conditions may not reproduce commercial foam structure.
7. High-potency labeling constraints. Treatment duration and body-surface limitations restrict volume expansion.
8. Substitution economics. Pharmacy substitution may favor lower-cost creams even when foam performance is better.
9. Regulatory delay. Complex topical products often require multiple development cycles before ANDA acceptance or approval.

How large is the commercial opportunity?

The opportunity is a niche dermatology market rather than a broad primary-care market. Revenue depends on prescription volume, payer coverage, generic discounting, and the ability to preserve a foam price premium.

Commercial value is highest in patients who:

• Need a super-high-potency corticosteroid for a limited course.
• Have scalp or hair-bearing lesions.
• Prefer a non-ointment vehicle.
• Have difficulty spreading creams over large plaques.
• Value rapid drying.
• Need an emollient vehicle because of dryness or scaling.

The market is less attractive where payers impose step edits favoring clobetasol cream, ointment, solution, or shampoo. A generic foam may still obtain premium placement if it reduces adherence problems or improves treatment completion, but those claims require clinical or real-world evidence.

A useful revenue model is:

Net revenue = treated patients × prescriptions per patient × units per prescription × net price per unit

The principal price variables are wholesale acquisition cost, mandatory rebates, specialty-pharmacy discounts, copay assistance, and the degree of generic substitution. Because treatment courses are typically limited, a developer should not assume chronic-use revenue patterns associated with maintenance dermatology products.

How should a developer build an OLUX-E excipient strategy?

A commercially disciplined development program should prioritize the reference product’s performance profile before pursuing cost reduction.

Recommended development sequence

1. Characterize the reference formulation and packaging system.
2. Map excipient functions rather than copying ingredient names alone.
3. Establish target ranges for foam density, collapse, spreadability, drying time, residue, and delivered dose.
4. Screen alternative grades of fatty alcohols, mineral oil, propylene glycol, surfactant, and propellant.
5. Evaluate active solubility and crystallization across temperature and humidity conditions.
6. Test valve, gasket, actuator, and canister compatibility.
7. Compare in vitro release and permeation behavior.
8. Conduct human sensory and usability studies.
9. Select a formulation that balances equivalence, cost, supply security, and patent clearance.
10. Lock the commercial container-closure system before pivotal bioequivalence work.

The preferred formulation is not necessarily the one with the lowest excipient cost. Raw-material savings can be offset by lower yield, filling losses, higher reject rates, stability failures, or weaker patient acceptance.

How strong is the commercial patent estate for OLUX-E?

The estate should be viewed as moderate in commercial relevance but potentially narrow in enforceability. The active ingredient does not create meaningful new-molecule exclusivity. Any remaining barriers are likely to arise from:

• Specific emollient foam compositions.
• Aerosol delivery configurations.
• Excipient combinations.
• Manufacturing and filling processes.
• Product-performance limitations.
• Method-of-use claims.

Formulation patents can delay competition only when their claims cover commercially necessary product attributes and remain valid after prior-art review. A generic developer with a credible design-around may reduce litigation exposure by changing excipient ratios, propellant architecture, or packaging components while retaining the essential clinical and delivery profile.

What licensing and partnering opportunities exist?

Licensing opportunities are most credible in three areas:

• A rights deal for an approved or near-approved generic foam.
• A formulation-platform license covering aerosol foam technology.
• A regional commercialization agreement for dermatology markets outside the United States.

Potential partners include generic manufacturers with aerosol filling capacity, dermatology companies with field sales teams, contract development and manufacturing organizations, and specialty-pharmacy distributors.

A license should address ownership and control of:

• Improvements to the excipient system.
• Device and actuator changes.
• Regulatory correspondence.
• Stability data.
• Manufacturing-process know-how.
• Patent prosecution and enforcement.
• Authorized-generic rights.
• Geographic launch sequencing.

Key Takeaways

• OLUX-E is a clobetasol propionate 0.05% emollient foam whose commercial differentiation comes from vehicle and delivery performance.
• Mineral oil, cetyl alcohol, stearyl alcohol, polysorbate 60, ethanol, propylene glycol, buffer components, water, and propellant work as an integrated system.
• The strongest generic opportunity is a formulation that matches foam behavior, spreadability, drying time, residue, and dose delivery at lower cost.
• The main technical risks are clobetasol crystallization, foam instability, valve compatibility, dose variability, and sensory mismatch.
• The key intellectual-property issues concern formulation, device, manufacturing, and method-of-use claims rather than active-ingredient exclusivity.
• Commercial upside is concentrated in patients who prefer foam delivery and in channels that tolerate a premium over clobetasol creams and ointments.
• An excipient redesign can create commercial value, but only if it preserves product performance and supports an efficient regulatory pathway.

Frequently Asked Questions

Is OLUX-E a biologic or a small-molecule drug?

OLUX-E is a topical small-molecule drug product containing clobetasol propionate. Biosimilar approval pathways do not apply.

Can a generic company change the excipients in OLUX-E?

A generic applicant may use different inactive ingredients when permitted by FDA requirements, but the product must meet applicable equivalence, safety, quality, performance, and labeling standards. Changes to the vehicle can affect topical bioequivalence.

What is the most valuable excipient in OLUX-E?

No single excipient determines the product’s value. The interaction among mineral oil, fatty alcohols, surfactant, solvent, humectant, and propellant produces the emollient foam profile.

Does OLUX-E have a biosimilar risk?

No. OLUX-E contains clobetasol propionate, not a biologic. Its competitive risk comes from generic topical corticosteroid products and alternative dosage forms.

Is an OLUX-E generic likely to compete on price alone?

Price is important but insufficient. A generic must also reproduce aerosol performance, patient-use characteristics, and pharmacy substitution economics. A lower-cost cream can remain the stronger competitor if payers do not value the foam delivery system.

References

1. U.S. Food and Drug Administration. (2009). OLUX-E (clobetasol propionate) foam, 0.05% prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: OLUX-E clobetasol propionate aerosol, foam.
3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2022). Guidance for industry: Topical dermatological drug product testing.